Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ofatumumab for treating relapsing multiple sclerosis ID1677

Final stakeholder list of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Company Novartis (ofatumumab) Patient/carer groups • Multiple Sclerosis Society • Multiple Sclerosis Trust Professional groups • Royal College of Physicians • UK Clinical Pharmacy Association Others • Department of Health and Social Care • NHS Rotherham CCG • NHS Surrey Downs CCG • NHS England • Welsh Government	General • All Wales Therapeutics and Toxicology Centre • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Final comparator companies • Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a) • Roche (ocrelizumab) • Janssen (ponesimod) Relevant research groups • None Associated Public Health groups • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.